In addition, in patients with advanced EGFR mutated NSCLC, co-alterations of cell cycle genes, such as CCND1/2, CCNE1, CDK4/6 were significantly associated with intrinsic resistance to osimertinib [28]. This evidence concerns the gene CDK4 and non-small cell lung carcinoma.